A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Background Inhibition of the programmed cell death protein 1 (PD‐1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies. Bruton tyrosine kinase (BTK) inhibition may suppress myeloid‐der...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Jg. 126; H. 20; S. 4485 - 4497
Hauptverfasser:	Zhang, Tian, Harrison, Michael R., O'Donnell, Peter H., Alva, Ajjai S., Hahn, Noah M., Appleman, Leonard J., Cetnar, Jeremy, Burke, John M., Fleming, Mark T., Milowsky, Matthew I., Mortazavi, Amir, Shore, Neal, Sonpavde, Guru P., Schmidt, Emmett V., Bitman, Bojena, Munugalavadla, Veerendra, Izumi, Raquel, Patel, Priti, Staats, Janet, Chan, Cliburn, Weinhold, Kent J., George, Daniel J.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Wiley Subscription Services, Inc 15.10.2020 John Wiley and Sons Inc
Schlagworte:	Alanine Alanine transaminase Anemia Apoptosis Bladder cancer Bruton's tyrosine kinase Cancer CD8 antigen Cell activation Cell death Correlation analysis Immune system Immunotherapy Kinases Lymphocytes Lymphocytes T Metastases Metastasis Monoclonal antibodies Monocytes Oncology Original Patients Pembrolizumab Platinum programmed cell death receptor 1 protein kinase inhibitor Protein-tyrosine kinase Solid tumors Suppressor cells Survival Targeted cancer therapy Tumors Tyrosine Urinary tract urologic neoplasms Urothelial cancer Urothelial carcinoma protein kinase inhibitor programmed cell death receptor 1 immunotherapy urologic neoplasms
ISSN:	0008-543X, 1097-0142, 1097-0142
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!